EGFR and Miyoshi myopathy: Also detailed are the in vivo targeting characteristics of 86Y-labeled panitumumab and cetuximab in three human MM tumor xenograft models in mice for potential use in risk stratification and quantitative non-invasive imaging of HER1, and assessment of mAb uptake in MM.